Digi International Expands Industry-Leading Portfolio of Connectivity Solutions for Private Cellular Networks, Supporting Transmission and Distribution for Utilities
Expanding its portfolio of solutions to support private cellular networks, Digi International (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) solutions, connectivity products, and services, today launched new versions of its widely adopted Digi IX10 cellular router at DistribuTECH 2023. The new solution enables electric utilities to deploy private cellular networks that leverage the CBRS Band 48 shared spectrum or Anterix Band 8 900 MHz licensed spectrum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005387/en/
Digi supports private networks in collaboration with third-party providers. (Photo: Business Wire)
Building upon its expansive portfolio of Private Cellular Network (PCN) enabled devices, Digi IX10 is a full-featured cellular router combining trouble-free reliability with long service life. Flexible power and connectivity options make it a versatile and cost-effective choice for electric utilities, smart-grid equipment manufacturers, and other stakeholders that need to secure critical infrastructure data transmission over private cellular networks — including variants for Anterix 900 MHz licensed spectrum and CBRS 3.5 GHz spectrum.
“In the utilities market, private broadband is rapidly emerging as a must-have for grid modernization efforts,” said Carlos L'Abbate, CTO from Anterix. “As the nation’s largest holder of licensed spectrum in the 900 MHz band, our Anterix Active Ecosystem welcomes Digi’s latest addition to its portfolio of PCN-enabled routers. Together, Digi and Anterix are uniquely positioned to help utilities achieve secure, resilient and customer-controlled operations.”
The new Digi solution is ideal for a range of use cases in the industrial and utilities sectors, including transmission and distribution automation, connecting grid assets, metering, power quality monitoring, and remote instrumentation, as well as EV charging, solar farms, and other utilities applications that require greater intelligence, visibility, and edge computing.
“When it comes to modernizing our grid infrastructure, connectivity remains among the most important requirements,” said Kinana Hussain, Vice President of Product Management, from Digi International. “The latest model of the Digi IX10 expands our PCN device portfolio and, coupled with Digi Remote Manager, reaffirms our commitment to providing the smart and affordable connectivity needed by stakeholders in the electric utilities industry.”
Digi’s PCN solutions feature Digi Remote Manager® (Digi RM), the command center enabling the orchestration, management, and visibility of PCN devices. Digi RM enables low/no-touch provisioning, mass configuration, maintenance, and support, even for thousands of devices. With Digi RM, utilities can evaluate, update, and configure Digi devices while gaining visibility into network health. Digi also offers an on-premise remote management option for deployments requiring full control, and customization of their networking infrastructure.
“Digi International has been a prominent member of the OnGo Alliance for many years,” said Alan Ewing, Executive Director of the OnGo Alliance. “The launch of the Digi IX10 for CBRS marks another milestone in the continued adoption of 4G LTE and 5G solutions using shared spectrum. This addition to the company’s broad portfolio of PCN solutions will offer utilities – and other companies as well – more deployment options as they strive to improve the resiliency of the nation’s grid infrastructure.”
IX10 Features & Benefits:
-
Design – Compact, economical and rugged, Digi IX10’s small footprint provides versatility in placement, and its specs ensure it can withstand broad temperature ranges, making it ideal for public or private cellular networks in harsh environments.
-
Flexibility – Wirelessly connects IP-based devices while protecting investments in legacy serial devices. Flexible power input and low-power consumption allows it to use existing DC power in control cabinets, as well as solar for remote installations.
-
Reliability – Redundant connectivity with dual SIMs and Digi SureLink® for failover from private to public networks, or dual-public networks.
- Security - Built-in Digi TrustFence® for device security, device identity and data privacy.
For pricing information, contact Digi International.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005387/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom